- Home
- QNCX vs PAVS Comparison
QNCX vs PAVS Comparison
Compare QNCX & PAVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QNCX
- PAVS
- Stock Information
- Founded
- QNCX 2012
- PAVS 2004
- Country
- QNCX United States
- PAVS United States
- Employees
- QNCX N/A
- PAVS N/A
- Industry
- QNCX Biotechnology: Biological Products (No Diagnostic Substances)
- PAVS Medicinal Chemicals and Botanical Products
- Sector
- QNCX Health Care
- PAVS Health Care
- Exchange
- QNCX Nasdaq
- PAVS Nasdaq
- Market Cap
- QNCX 70.4M
- PAVS 90.2M
- IPO Year
- QNCX 2019
- PAVS 2019
- Fundamental
- Price
- QNCX $1.60
- PAVS $1.36
- Analyst Decision
- QNCX Strong Buy
- PAVS
- Analyst Count
- QNCX 4
- PAVS 0
- Target Price
- QNCX $9.50
- PAVS N/A
- AVG Volume (30 Days)
- QNCX 130.8K
- PAVS 12.8K
- Earning Date
- QNCX 11-13-2024
- PAVS 01-01-0001
- Dividend Yield
- QNCX N/A
- PAVS N/A
- EPS Growth
- QNCX N/A
- PAVS N/A
- EPS
- QNCX N/A
- PAVS N/A
- Revenue
- QNCX N/A
- PAVS $6,544,819.00
- Revenue This Year
- QNCX N/A
- PAVS N/A
- Revenue Next Year
- QNCX N/A
- PAVS N/A
- P/E Ratio
- QNCX N/A
- PAVS N/A
- Revenue Growth
- QNCX N/A
- PAVS N/A
- 52 Week Low
- QNCX $0.51
- PAVS $0.32
- 52 Week High
- QNCX $2.45
- PAVS $2.52
- Technical
- Relative Strength Index (RSI)
- QNCX 43.92
- PAVS 56.61
- Support Level
- QNCX $1.49
- PAVS $1.31
- Resistance Level
- QNCX $1.69
- PAVS $1.38
- Average True Range (ATR)
- QNCX 0.14
- PAVS 0.05
- MACD
- QNCX 0.00
- PAVS -0.01
- Stochastic Oscillator
- QNCX 46.15
- PAVS 50.00
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing innovative precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics.
About PAVS Paranovus Entertainment Technology Ltd.
Paranovus Entertainment Technology Ltd through its subsidiary, is engaged in the AI-powered entertainment industry, aiming to provide users with AI-driven games and applications to deliver immersive and engaging entertainment experiences. It is planning to launch SimTwin application which will allow users to interact with digital versions of people and capture life moments. The company also has a software development agreement with Blueline Studios Inc which is developing 10,000 Lives, a mobile game where players pursue various careers and life goals using a board game mechanic.